Prime Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PRME Nasdaq 2836 primemedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Prime Medicine, Inc.

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Aug 6th, 2026 7:50 am
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 6:00 am
Scribe’s Genetic Editing Aims to Prevent Heart Attacks - Jul 30th, 2026 8:26 am
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Jul 30th, 2026 8:00 am
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - Jul 23rd, 2026 2:05 pm
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Jul 15th, 2026 8:01 am
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Jul 15th, 2026 2:53 am
Cathie Wood Dumps AMD, Doubles Down on Meta Stock - Jul 10th, 2026 6:57 am
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Jul 9th, 2026 2:14 pm
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle - Jul 8th, 2026 2:09 pm
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Jul 8th, 2026 10:47 am
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - Jul 8th, 2026 6:00 am
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Jul 8th, 2026 3:07 am
Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” - Jul 5th, 2026 4:07 pm
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Jul 3rd, 2026 5:42 am
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) - Jun 22nd, 2026 6:00 am
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease - Jun 18th, 2026 6:00 am
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - Jun 15th, 2026 2:30 pm
We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate - Jun 4th, 2026 6:29 am
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference - Jun 3rd, 2026 6:00 am